Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor

NCT04122339 is registered in ClinicalTrials.gov with Maxinovel Pty., Ltd. as lead sponsor.

NCT NCT04122339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04122339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Lead sponsor
Maxinovel Pty., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
February 11, 2020
Completion date
November 1, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor